Time is running out for covid vaccines, home testing kits, and even some treatments offered free to consumers.
The White House announced this month that the national public health emergency, originally declared in early 2020 in response to the pandemic, will expire on May 11. When it ends, so will many policies designed to combat the spread of the virus.
Please vaccinate. So far, the federal government has purchased covid-19 shots. The company recently purchased 105 million doses of his Pfizer-BioNTech bivalent booster for about $30.48 a dose and 66 million doses of Moderna’s version for him at $26.36 a dose. (These are among the companies that developed the first covid vaccines sold in the United States.)
As long as government-purchased supplies continue, people will have access to these vaccines at low or no cost. But even before the public emergency end date was set, Congress chose not to provide more funding to increase the government’s dwindling stockpile. We were already planning to enter the commercial market. Insurance companies and government health programs may negotiate lower prices, but both companies have suggested raising prices in the range of $110 to $130 at a time.
“We’re looking at double-digit billion dollars.[-dollar] Investors were quoted by Ryan Richardson, Chief Strategy Officer of BioNTech, at JP Morgan’s recent conference in San Francisco. The company expects the total price (the full price before discounts) to be $110 per dose, which is “more than justified from a health economics perspective,” Richardson said.
Even if the vaccine is slow to spread, this could translate into tens of billions of dollars in revenue for manufacturers. The consumer then pays the bill either directly or indirectly.
According to a recent KFF report, if half of adults (roughly the same proportion as those who opt for annual flu shots) get covid boosters at new higher prices, insurers, employers and other payers will pay $12.4 billion to $14.8 billion. That’s the average price paid by the federal government, roughly double what it would cost every adult in the US to get her bivalent booster.
As for COVID treatments, an August blog post by the Department of Health and Human Services’ Office for Strategic Preparedness and Response said supplies of the government-purchased drug Paxlovid were expected to last until mid-year before the private sector takes over. The government bulk purchase price from manufacturer Pfizer is $530 for a course of treatment, and it’s not yet known how much the company will charge when government supplies run out.
To what extent will consumers feel the pinch?
One thing is certain: how much of the increased cost is passed on to consumers will depend on health insurance coverage.
Medicare beneficiaries, people enrolled in Medicaid (the federal government’s health insurance program for low-income individuals), and people covered by the Affordable Care Act are eligible for public health emergencies. Quit, the government runs out of vaccines. Many people with occupational-based insurance are also less likely to face vaccine copayments unless they go outside the network for vaccinations. A person may have to pay for all or part of the vaccination. Also, those without insurance must either pay the full cost out-of-pocket or get free or low-cost vaccinations from local clinics or other health care providers. Some uninsured patients may be forced to skip immunizations and tests if free or low-cost options are not found.
Coming up with something that could cost over $100 to inoculate would be especially difficult. Sean Robbins, executive vice president of external affairs for the Blue Cross and Blue Shield Association, said: These increases will also affect policyholders as costs “flow into premiums,” he said.
Meanwhile, public policy experts say many private insurers will continue to cover paxlovid, but patients may still have to pay out-of-pocket costs, at least until they meet the deductible, like other drugs. I have. Medicaid will continue to cover patients at no cost until at least he 2024. However, Medicare coverage is limited until the treatment goes through the normal FDA process. This will take longer than the Emergency Use Authorization for which it is sold.
Another complication is that the uninsured roll is likely to rise over the next year as states prepare to revive the process of regularly determining Medicaid eligibility. This was stopped during the pandemic. States will begin reassessing whether Medicaid participants meet income and other eligibility requirements, he said, starting in April.
Nationwide, an estimated 5 to 14 million people could lose their insurance.
“This is our biggest concern right now,” said John Baackes, CEO of LA Care, the nation’s largest public health plan with 2.7 million members.
“They may not realize they’ve lost coverage until they go to fill out a prescription or seek other medical care, including vaccinations.
What about Covid test kits?
Until the public health emergency is over, the rule remains that insurance companies, including Medicare and Affordable Care Act plans, will pay for up to eight home testing kits per month for each person covered by the plan. Applies.
For consumers, including those without insurance, government websites are offering up to four test kits per household until they run out. The Biden administration shifted funds to purchase additional kits and made them available in late December.
However, starting in May, former Medicare beneficiaries and many people with private work-based insurance will have to start copaying for rapid antigen test kits. Some Medicare Advantage Plans that are , may choose to continue to cover you at no out-of-pocket cost. Please check with your insurance company as it varies by insurance company. Medicaid subscribers will also continue to receive free test kits for a little over a year.
State rules may also vary, and some health plans continue to cover non-shared costs for COVID-19 testing, treatment, and vaccines after the health emergency ends. may be possible.
Overall, the future of covid testing, vaccines, and treatments will reflect the complex mix that consumers already navigate for most other types of care.
“From a consumer perspective, the vaccine will remain free, but many people will face costs for treatment and test kits,” said Jen Cates, senior vice president of the KFF. “We have universal access and are now saying we are back to the normal US healthcare system.”
KHN correspondent Darius Tahir contributed to this report.
KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism on health issues. KHN is one of the three main operating programs of KFF (Kaiser Family Foundation), along with policy analysis and polls. KFF is a donated non-profit organization that provides information on health issues to the public.
